AI Article Synopsis
- - The study investigates a potential vaccine, VSVΔG/EBOVgp, derived from the vesicular stomatitis virus modified to express Ebola virus glycoprotein, aimed at combating the 2014 Ebola outbreak.
- - Researchers analyzed the immune response by examining mRNA sequences in PBMCs from macaques after vaccination and exposure to the Ebola virus.
- - Findings indicate a well-regulated immune response that adjusts as the virus is cleared, suggesting the vaccine's safety and effectiveness in prompting an appropriate immune reaction.
Article Abstract
Vesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak. To characterize the host response to this vaccine, we used mRNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from cynomolgus macaques after VSVΔG/EBOVgp immunization and subsequent EBOV challenge. We found a controlled transcriptional response that transitioned to immune regulation as the EBOV was cleared. This observation supports the safety of the vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340895 | PMC |
| http://dx.doi.org/10.1128/CVI.00733-14 | DOI Listing |
Publication Analysis
Top Keywords
ebola virus
16
zaire ebola
12
cynomolgus macaques
8
vesicular stomatitis
8
stomatitis virus
8
virus expressing
8
expressing zaire
8
glycoprotein vsvΔg/ebovgp
8
virus
6
next-generation sequencing
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!